Clinical Trials Testing Sapropterin's Impact
Sapropterin (Kuvan), approved for phenylketonuria (PKU), underwent multiple clinical trials measuring its effects on blood phenylalanine (Phe) levels, the key biomarker for PKU control. The pivotal Phase 3 trial (PKU-004) enrolled 245 patients and tracked Phe reduction over 6 weeks, with responders (≥30% drop) continuing for 8 more weeks. It showed 56% of patients on 20 mg/kg/day had sustained Phe drops vs. 6% on placebo.[1][2]
How Trials Measured Responsiveness
Trials used Phe blood tests at baseline, week 2, week 6, and week 8, plus dietary Phe intake logs. A Phase 2 study (PKU-002) tested doses from 5-20 mg/kg, confirming dose-dependent Phe lowering in 62% of adults.[3] Long-term open-label extensions (up to 7 years) monitored sustained impact, with 20-30% average Phe reduction in responders.[2]
Real-World and Post-Approval Studies
Post-marketing studies like PKUAS (PKU Active Source) tracked over 4,000 patients, showing 51% response rates via Phe monitoring.[4] Pediatric trials (PKU-006) in kids aged 4+ confirmed similar impacts, with 37% responders.[1]
Who Responds and Limitations
About 20-50% of PKU patients respond, identified by 4-week Phe tests. Non-responders show no benefit. Trials excluded severe cases; impact fades without ongoing dosing.[2][3]
[1]: FDA Label for Kuvan
[2]: BioMarin Clinical Overview
[3]: NEJM 2007 Trial (PKU-001/002)
[4]: DrugPatentWatch.com - Sapropterin Studies